Amyloid beta peptide membrane perturbation is the basis for its biological effects

Neurochemical Research

Volumn 24, Issue 12, 1999, Pages 1621-1630

  Kanfer, Julian N ^a   Sorrentino, Giuseppe ^b   Sitar, Daniel S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Alzheimer's disease; Amyloid peptide; A P; Membranes; Neurodegeneration; Perturbation; Receptors; Therapeutics

Indexed keywords

AMYLOID BETA PROTEIN; FREE RADICAL; MEMBRANE PROTEIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CELL MEMBRANE; DRUG ACTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; MEMBRANE PERMEABILITY; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0032699297     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021172620295     Document Type: Article

References (112)

1. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16:409-414.
2. Butterfield, D. A. 1997. β-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem. Res. Toxicol. 10:495-506.
3. Wood, S. J., Wetzel, R., Martin, J. D., and Hurle, M. R. 1995. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4. Biochemistry 34:724-730.
4. Soto, C., Kindy, M. S., Baumann, M., and Frangione, B. 1996. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem. Biophys. Res. Commun. 226: 672-680.
5. Brenneman, D. E., and Gozes, I. 1996. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97:2299-2307.
6. Brenneman, D. E., Hauser, J., Neale, E., Rubinraut, S., Fridkin, M., Davidson, A., and Gozes, I. 1998. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther. 285:619-627.
7. Blanchard, B. J., Konopka, G., Russell, M., and Ingram, V. M. 1997. Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease. Brain Res. 776:40-50.
8. Smith, M. A. 1998. Alzheimer disease. Int. Rev. Neurobiol. 42:1-54.
9. Yankner, B. A., Duffy, L. K., and Kirschner, D. A. 1990. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250:279-282.
10. Kirschner, D. A., Abraham, C., and Selkoe, D. J. 1986. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibres in Alzheimer disease indicates cross-βconformation. Proc. Natl. Acad. Sci. USA 83:503-507.
11. Pike, C. J., Walencewicz-Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., and Cotman, C. W. 1995. Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J. Neurochem. 64:253-265.
12. Singh, I. N., Sato, K., Takashima, A., and Kanfer, J. N. 1997. Activation of LA-N-2 cell phospholipases by single alanine substitution analogs of amyloid β peptide (25-35). FEBS Lett. 405:65-67.
13. Kanfer, J. N., Sorrentino, G., and Sitar, D. S. 1998. Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease. Neurosci. Lett. 257:93-96.
14. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95:6448-6453.
15. Terzi, E., Hölzemann, G., and Seelig, J. 1994. Alzheimer β-amyloid peptide 25-35: electrostatic interactions with phospholipid membranes. Biochemistry 33:7434-7441.
16. Terzi, E., Hölzemann, G., and Seelig, J. 1997. Interaction of Alzheimer β-amyloid peptide (1-40) with lipid membranes. Biochemistry 36:14845-14852.
17. McLaurin, J., and Chakrabartty, A. 1996. Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. J. Biol. Chem. 271:26482-26489.
18. McLaurin, J., and Chakrabartty, A. 1997. Characterization of the interactions of Alzheimer β-amyloid peptides with phospholipid membranes. Eur. J. Biochem. 245:355-363.
19. MI-containing membranes. FEBS Lett. 402:95-98.
20. Avdulov, N. A., Chochina, S. V., Igbavboa, U., Warden, C. S., Vassiliev, A. V., and Wood, W. G. 1997. Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69:1746-1752.
21. Pillot, T., Goethals, M., Vanloo, B., Talussot, C., Brasseur, R., Vandekerckhove, J., Rosseneu, M., and Lins, L. 1996. Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide. J. Biol. Chem. 271:28757-28765.
22. Mason, R. P., Estermyer, J. D., Kelly, J. F., and Mason, P. E. 1996. Alzheimer's disease amyloid β peptide 25-35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis. Biochem. Biophys. Res. Commun. 222:78-82.
23. Good, T. A., and Murphy, R. M. 1995. Aggregation state-dependent binding of β-amyloid peptide to protein and lipid components of rat cortical homogenates. Biochem. Biophys. Res. Commun. 207:209-215.
24. Schulz, J. G., Megow, D., Reszka, R., Villringer, A., Einhäupl, K. M., and Dirnagl, U. 1998. Evidence that glypican is a receptor mediating β-amyloid neurotoxicity in PC12 cells. Eur. J. Neurosci. 10:2085-2093.
25. Müller, W. E., Koch, S., Eckert, A., Hartmann, H., and Scheuer, K. 1995. β-Amyloid peptide decreases membrane fluidity. Brain Res. 674:133-136.
26. Avdulov, N. A., Chochina, S. V., Igbavboa, U., O'Hare, E. O., Schroeder, F., Cleary, J. P., and Wood, W. G. 1997. Amyloid β-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J. Neurochem. 68:2086-2091.
27. Müller, W. E., Eckert, G. P., Scheuer, K., Cairns, N. J., Maras, G., and Gattaz, W. F. 1998. Effects of β-amyloid peptides on the fluidity of membranes from frontal and parietal lobes of human brain. High potencies of Aβ1-42 and Aβ1-43. Amyloid: Int. J. Exp. Clin. Invest. 5:10-15.
28. +2-channel hypotheses for neuronal death in Alzheimer disease. Mol. Cell. Biochem. 140:119-125.
29. 2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J. 73:67-75.
30. Brasseur, R., Pillot, T., Lins, L., Vandekerckhove, J., and Rosseneu, M. 1997. Peptides in membranes: tipping the balance of membrane stability. Trends Biochem. Sci. 22:167-171.
31. Zubenko, G. S. 1986. Hippocampal membrane alteration in Alzheimer's disease. Brain Res. 385:115-121.
32. Hajimohammadreza, I., and Brammer, M. 1990. Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci. Lett. 112:333-337.
33. Scheuer, K., Maras, A., Gattaz, W. F., Cairns, N. J., Forstl, H., and Muller, W. E. 1996. Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. Dementia 7:210-214.
34. Mecocci, P., Cherubini, A., Beal, M. F., Acchetti, R., Chionne, F., Polidori, M. C., Romano, G., and Senin, U. 1996. Altered mitochondrial membrane fluidity in AD brain. Neurosci. Lett. 207:129-132.
35. Zubenko, G. S., Cohen, B. M., Boller, F., Malinakova, I., Keefe, N., and Chojnacki, B. 1987. Platelet membrane abnormality in Alzheimer's disease. Ann. Neurol. 22:237-244.
36. Zubenko, G. S., Teply, I., Winwood, E., Huff, F. J., Moossy, J., Sunderland, T., and Martinez, A. J. 1996. Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer's disease: results at 5 years. Am. J. Psychiatry 153: 420-423.
37. Piletz, J. E., Sarasua, M., Whitehouse, P., and Chotani, M. 1991. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol. Aging 12:401-406.
38. Scott, R. B., Collins, J. M., and Hunt, P. A. 1994. Alzheimer's disease and Down syndrome: leukocyte membrane fluidity alterations. Mech. Ageing Dev. 75:1-10.
39. Kuo, Y.-M., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., and Roher, A. E. 1999. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 257:787-791.
40. deJonge, H. W., Dekkers, D. H. W., Bastiaanse, E. M. L., Bezstarosti, K., van der Laarse, A., and Lamers, J. M. J. 1996. Eicosapentaenoic acid incorporation in membrane phospholipids modulates receptor-mediated phospholipase C and membrane fluidity in rat ventricular myocytes in culture. J. Mol. Cell. Cardiol. 28:1097-1108.
41. Tappia, P. S., Ladha, S., Clark, D. C., and Grimble, R. F. 1997. The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets. Mol. Cell. Biochem. 166:135-143.
42. Singh, J. K., Dasgupta, A., Adayev, T., Shahmehdi, S. A., Hammond, D., and Banerjee, P. 1996. Apoptosis is associated with an increase in saturated fatty acid containing phospholipids in the neuronal cell line, HN2-5. Biochim. Biophys. Acta 1304:171-178.
43. Hochgraf, E., Mokady, S., and Cogan, U. 1997. Dietary oxidized linoleic acid modifies lipid composition of rat liver microsomes and increases their fluidity. J. Nutr. 127:681-686.
44. Naisberg, Y., and Weizman, A. 1997. Role of lipid-induced changes in plasma membrane in the biophysical shunt theory of psychopathology. Med. Hypotheses 48:277-280.
45. Gimpl, G., Burger, K., and Fahrenholz, F. 1997. Cholesterol as a modulator of receptor function. Biochemistry 36:10959-10974.
46. Mason, R. P., Shoemaker, W. J., Shajenko, L., Chambers, T. E., and Herbette, L. G. 1992. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 13:413-419.
47. Ginsberg, L., Xuereb, J. H., and Gershfeld, N. L. 1998. Membrane instability, plasmalogen content, and Alzheimer's disease. J. Neurochem. 70:2533-2538.
48. Roth, G. S., Joseph, J. A., and Mason, R. P. 1995. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci. 18:203-206.
49. Young, A. B., and Penney, J. B. Jr. 1994. Neurotransmitter receptors in Alzheimer's disease. Pages 293-303, in Terry, R. D., Katzman, R., and Bick, K. L. (eds.), Alzheimer's Disease, Raven Press Ltd., New York.
50. Zubenko, G. S. 1997. Molecular neurobiology of Alzheimer's disease (syndrome). Harv. Rev. Psychiatry 5:177-213.
51. Davies, P., and Maloney, A. J. F. 1976. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403-1403.
52. Kasa, P., Rakonczay, Z., and Gulya, K. 1997. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52:511-535.
53. Rodriguez-Puertas, R., Pascual, J., Vilaro, T., and Pazos, A. 1997. Autoradiographic distribution of M1, M2, M3 and M4 muscarinic subtypes in Alzheimer's disease. Synapse 26: 341-350.
54. Flynn, D. D., Ferrari-DiLeo, G., Levey, A. I., and Mash, D. C. 1995. Differential alterations in muscarininc receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci. 56:869-876.
55. Greenwood, A. F., Powers, R. E., and Jope, R. S. 1995. Phosphoinositide hydrolysis, Gαq, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease. Neuroscience 69:125-138.
56. Shimohama, S., Sasaki, Y., Fujimoto, S., Kamiya, S., Taniguchi, T., Takenawa, T., and Kimura, J. 1998. Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease. Neuroscience 82:999-1007.
57. Zhang, D., Dhillon, H., Prasad, M. R., and Markesbery, W. R. 1998. Regional levels of brain phospholipase Cγ in Alzheimer's disease. Brain Res. 811:161-165.
58. Jansen, K. L. R., Faull, R. L. M., Dragunow, M., and Synek, B. L. 1990. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors-an autoradiographic study. Neuroscience 39:613-627.
59. A receptor complex function in frontal cortex membranes from control and neurological patients. Eur. J. Pharmacol. 197:33-39.
60. A, muscarinic and β adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer's disease. J. Neurochem. 57:282-290.
61. Armstrong, D. M., and Ikonomovic, M. D. 1996. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer disease. Evidence for hippocampal plasticity. Mol. Chem. Neuropathol. 28:59-64.
62. 123I]-IBZM. Neurology 47: 1065-1068.
63. Joyce, J. N., Kaeger, C., Ryoo, H., and Goldsmith, S. 1993. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease. Neurosci. Lett. 154:171-174.
64. 3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol. Aging 12:131-136.
65. 2-adrenoreceptors in Alzheimer's disease: an autoradiographic study in frontal cortex and hippocampus. Neurosci. Lett. 142:36-40.
66. 2 receptors in prefrontal cortex and hippocampus. J. Neurochem. 53: 1772-1781.
67. Lemmer, B., Langer, L., Ohm, T., and Bohl, J. 1993. Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease. Naunyn Scheimedebergs Arch. Pharmacol. 347:214-219.
68. Russo-Neustadt, A., and Cotman, C. W. 1997. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J. Neurosci. 17:5573-5580.
69. 18F] setoperone. Brain 116:497-510.
70. 3H] GR113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders. Behav. Brain Res. 73: 249-252.
71. Barnes, N. M., Costall, B., Naylor, R. J., Williams, T. J., and Wischik, C. M. 1990. Normal densities of 5-HT3 receptor recognition sites in Alzheimer's disease. Neuroreport 1:253-254.
72. Chen, C. P. L.-H., Alder, J. T., Bowen, D. M., Esiri, M. M., McDonald, B., Hope, T., Jobst, K. A., and Francis, P. T. 1996. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J. Neurochem. 66:1592-1598.
73. Jaarsma, D., Sebens, J. B., and Korf, J. 1991. Reduction of adenosine A ,-receptors in the perforant pathway terminal zone in Alzheimer hippocampus. Neurosci. Lett. 121: 111-114.
74. Ulas, J., Brunner, L. C., Nguyen, L., and Cotman, C. W. 1993. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience 52:843-854.
75. 1 and κ1 opioid receptors in the striatum in Alzheimer's disease. Brain Res. 616: 211-217.
76. Mackay, K. B., Dewar, D., and McCulloch, J. 1994. Kappa-1 opioid receptors of the temporal cortex are preserved in Alzheimer's disease. J. Neural Transm. Park. Dis. Dement. Sect. 7:73-79.
77. 1 opioid receptor recognition site density and regulation by G-proteins in the temporal cortex of patients with Alzheimer's disease. Neurosci. Lett. 185:131-134.
78. Barg, J., Belcheva, M., Rowinski, J., Ho, A., Burke, W. J., Chung, H. D., Schmidt, C. A., and Coscia, C. J. 1993. Opioid receptor density changes in Alzheimer amygdala and putamen. Brain Res. 632:209-215.
79. Kowall, N. W., Beal, M. F., Busciglio, J., Duffy, L. K., and Yankner, B. A. 1991. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA 88:7247-7251.
80. 4 25-35, mimics the function of substance P on modulation of nicotine-evoked secretion and desensitization in cultured bovine adrenal chromaffin cells. J. Neurochem. 60: 1163-1166.
81. Kimura, H., and Schubert, D. 1993. Amyloid β-protein activates tachykinin receptors and inositol triphosphate accumulation by synergy with glutamate. Proc. Natl. Acad. Sci. USA 90:7508-7512.
82. Di Stefano, M., Aleppo, G., Casabona, G., Genazzani, A. A., Scapagnini, U., and Nicoletti, F. 1993. Amyloid β protein does not interact with tachykinin receptors coupled to inositol phospholipid hydrolysis in human astrocytoma cells. Brain Res. 600:166-168.
83. Shimohigashi, Y., Matsumoto, H., Takano, Y., Saito, R., Iwata, T., Kamiya, H., and Ohno, M. 1993. Receptor-mediated specific biological activity of a β-amyloid protein fragment for NK-1 substance P receptors. Biochem. Biophys. Res. Commun. 193:624-630.
84. Burgevin, M. C., Daniel, N., Doble, A., and Blanchard, J. C. 1992. The trophic effect of beta-amyloid 25-35 peptide is not mediated by NK1 or bombesin receptors. Neuroreport 3: 1131-1134.
85. Rovero, P., Patacchini, R., Renzetti, A. R., Brown, M., Mizrahi, J., Maggi, C. A., and Giachetti, A. 1992. Interaction of amyloid β protein (25-35) with tachykinin receptors. Neuropeptides 22:99-101.
86. Boland, K., Manias, K., and Perlmutter, D. H. 1995. Specificity in recognition of amyloid-β peptide by the serpin-enzyme complex receptor in hepatoma and neuronal cells. J. Biol. Chem. 270:28022-28028.
87. Joslin, G., Krause, J. E., Hershey, A. D., Adoms, S. P., Fallon, R. J., and Perlmutter, D. H. 1991. Amyloid-β peptides, substance P and bombesin bind to the serpin-enzyme complex receptor. J. Biol. Chem. 266:21897-21902.
88. Schubert, D. 1997. Serpins inhibit the toxicity of amyloid peptides Eur. J. Neurosci. 9:770-777.
89. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. 1996. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
90. Dickson, D. W., Sinicropi, S., Yen, S. H., Ko, L. W., Mattiace, L. A., Bucala, R., and Vlassara, H. 1996. Glycation and microglia reaction lesions of Alzheimer's disease. Neurobiol. Aging 17:733-743.
91. Yan, S. D., Zhu, H., Fu, J., Yan, S. F., Roher, A., Tourtellotte, W. W., Rajavashkisth, T., Chen, X., Godman, G. C., Stern, D., and Schmidt, A. M. 1997. Amyloid-β peptide receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulatory factor: a proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA 94:5296-5301.
92. Takeda, A., Yasuda, T., Miyata, T., Mizuno, K., Li, M., Yoneyama, S., Horie, K., Maeda, K., and Sobue, G. 1996. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci. Lett. 221:17-20.
93. Takeda, A., Yasuda, T., Miyata, T., Goto, Y., Wakai, M., Watanabe, M., Yasuda, Y., Horie, K., Inagaki, T., Doyu, M., Maeda, K., and Sobue, G. 1998. Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer's disease brain. Acta Neuropathol. 95:555-558.
94. Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., Koike, T., Wakayama, I., Yanagihara, R., Garruto, R., Amano, N., and Makita, Z. 1998. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153:1149-1155.
95. Tabaton, M., Perry, G., Smith, M., Vitek, M., Angelini, G., Dapino, D., Garibaldi, S., Zaccheo, D., and Odetti, P. 1997. Is amyloid beta-protein glycated in Alzheimer's disease? Neuroreport 8:907-909.
96. Liu, G., Dargusch, R., and Schubert, D. 1997. Beta amyloid toxicity does not require RAGE protein. Biochem. Biophys. Res. Commun. 237:37-40.
97. Carette, B., Poulain, P., and Delacourte, A. 1993. Electrophysiological effects of 25-35 amyloid-β-protein on guinea-pig lateral septal neurons. Neurosci. Lett. 151:111-114.
98. Wu, J., Anwyl, R., and Rowan, M. J. 1995. β-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. Neuroreport 6:2409-2413.
99. Gray, C. W., and Patel, A. J. 1995. Neurodegeneration mediated by glutamate and β-amyloid peptide: a comparison and possible interaction. Brain Res. 691:169-179.
100. Le, W.-D., Colom, L. V., Xie, W.-j., Smith, R. G., Alexianu, M., and Appel, S. H. 1995. Cell death induced by β-amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Brain Res. 686:49-60
101. Cullen, W. K., Wu, J., Anwyl, R., and Rowan, M. J. 1996. β-Amyloid produces a delayed NMDA receptor-dependant reduction in synaptic transmission in rat hippocampus. Neuroreport 8:87-92.
102. 3H]MK-801 binding to rat cortical membranes in the presence of glutamate and glycine. J. Neurochem. 60:2297-2303.
103. 3H]MK-801 binding to rat cortical membranes. Neuroreport 5:405-408.
104. Cowburn, R. F., Wiehager, B., Trief, E., Li-Li, M., and Sundstrom, E. 1997. Effects of β-amyloid-(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem. Res. 22: 1437-1442.
105. Copani, A., Bruno, V., Battaglia, G., Leanza, G., Pellitteri, R., Russo, A., Stanzani, S., and Nicoletti, F. 1995. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by β-amyloid peptide. Mol. Pharmacol. 47:890-897.
106. 2 in LA-N-2 cells. Alzheimer's Res. 2:121-128.
107. Singh, I. N., Sorrentino, G., Sitar, D. S., and Kanfer, J. N. 1998. (-)Nicotine inhibits the activations of phospholipases A2 and D by amyloid β peptide. Brain Res. 800:275-281.
108. Singh, I. N., Sorrentino, G., and Kanfer, J. N. 1997. Amyloid β protein (25-35) stimulation of phospholipase C in LA-N-2 cells. J. Neurochem. 69: 252-258.
109. Sorrentino, G., Singh, I. N., Massarelli, R., and Kanfer, J. N. 1996. Stimulation of phospholipase C activity by norepinephrine, t-ACPD and bombesin in LA-N-2 cells. Eur. J. Pharmacol. 308:81-86.
110. Singh, I. N., Sorrentino, G., and Kanfer, J. N. 1998. Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35). Neurochem. Res. 23: 1225-1232.
111. Kelly, J. F., Furukawa, K., Barger, S. W., Rengen, M. R., Mark, R. J., Blanc, M., Roth, G. S., and Mattson, M. P. 1996. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. USA 93:6753-6758.
112. Cribbs, D. H., Pike, C. J., Weinstein, S. L., Velazquez, P., and Cotman, C. W. 1997. All-D-enantiomers of β-amyloid exhibit similar biological properties to all-L-amyloids. J. Biol. Chem. 272:7431-7436.